GlassScriptPhysician profile
Kathleen Lukaszewski
NPI 1356321251
$5,089.76
in general payments reported to CMS, 2019-2025
37 companies · $734 in 2025
The $734 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $236 · 2021: $615 · 2022: $739 · 2023: $1,017 · 2024: $954 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,705.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,605.77 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $455.76 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $389.14 | 2019-2025 | |
| Janssen Biotech, INC. | $326.98 | 2020-2025 | Stelara, Remicade, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.16 | 2019-2025 | Xifaxan |
| Celgene Corporation | $256.96 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $150.56 | 2022-2025 | Dupixent |
| Genzyme Corporation | $144.96 | 2022-2025 | |
| Braintree Laboratories, INC. | $128.58 | 2019-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $121.76 | 2020-2024 | Ocaliva |
| Madrigal Pharmaceuticals | $120.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $93.34 | 2019-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $87.48 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $80.30 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $79.11 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofire Diagnostics, LLC | $68.00 | 2019 | |
| Merck Sharp & Dohme LLC | $60.21 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $53.38 | 2024-2025 | Iqirvo |
| Allergan, INC. | $52.88 | 2019 | |
| Ardelyx, INC. | $52.08 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $50.08 | 2024-2025 | Vegzelma |
| Boston Scientific Corporation | $45.59 | 2020-2023 | Compliance Endokit |
| Qol Medical, LLC | $39.08 | 2021-2022 | |
| Ucb, INC. | $35.01 | 2019 | |
| Gilead Sciences, INC. | $29.68 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $28.31 | 2020-2023 | Linzess |
| Redhill Biopharma INC. | $26.84 | 2021 | |
| Fujifilm Healthcare Americas Corporation | $26.53 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.56 | 2025 | Wainua |
| Novartis Pharmaceuticals Corporation | $19.97 | 2024 | |
| Aimmune Therapeutics, INC. | $19.39 | 2024 | |
| Lilly USA, LLC | $18.82 | 2024 | Omvoh |
| Amgen INC. | $18.20 | 2020 | |
| Alnylam Pharmaceuticals INC. | $15.89 | 2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.44 | 2024 | Cyltezo |
| Evoke Pharma, INC. | $14.84 | 2023 | Gimoti |
| Alfasigma USA, INC. | $14.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Lukaszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.